Stockreport

ReShape Lifesciences sees 55.4% fall in Y/Y expenses in 2024 with cost cut plan [Seeking Alpha]

ReShape Lifesciences, Inc.  (RSLS) 
US:NASDAQ Investor Relations: ir.enteromedics.com
PDF next generation, enhanced Lap-Band 2.0 FLEX, with the plan expected to result in lower operating expenses of approximately $7.9 million in 2024 compared to $17.7 million [Read more]